Company Filing History:
Years Active: 1991-2022
Title: Edwin Richard Smith: Innovator in Cancer Therapy
Introduction
Edwin Richard Smith is a prominent inventor based in Chicago, IL (US), known for his significant contributions to cancer therapy through innovative research and development. With a total of 5 patents, Smith has made strides in the field of molecular biology, particularly in targeting complex mechanisms involved in cancer progression.
Latest Patents
Among his latest patents, Smith has developed small molecules aimed at disrupting the super elongation complex (SEC) and inhibiting transcription elongation for cancer therapy. These compounds are designed to inhibit transcription by RNA Polymerase II (Pol II) and target diseases associated with high levels of SEC-dependent gene expression, particularly cancers. Another notable patent involves therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (MLL-r). This method includes administering therapeutic agents that inhibit the biological activity of members of the interleukin-1 signaling pathway, providing new avenues for treating MLL-r leukemia.
Career Highlights
Throughout his career, Edwin Richard Smith has worked with esteemed institutions such as Northwestern University and Viskase Corporation. His work has not only advanced scientific understanding but has also contributed to the development of potential therapies for challenging medical conditions.
Collaborations
Smith has collaborated with notable colleagues, including Ali Shilatifard and Kaiwei Liang, enhancing the impact of his research through shared expertise and innovative ideas.
Conclusion
Edwin Richard Smith's contributions to cancer therapy through his patents and collaborations highlight his role as a key innovator in the field. His work continues to inspire advancements in medical research and treatment options for cancer patients.